Navigation Links
Access Pharmaceuticals to Host Update Conference Call for Investors
Date:3/1/2011

DALLAS and NEW YORK, March 1, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, will host a conference call on Wednesday, March 23rd to update investors on its ongoing commercial and development strategy. Management will discuss the progress made within each of Access' programs, including an update on commercial launch activities and schedule for MuGard, the company's oral mucositis supportive care product; its Cobalamin CobOral and CobaCyte programs, as well as the advancement of both its Thiarabine Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center, and ProLindac phase 2 combination trial in recurrent ovarian cancer.

The conference call is scheduled to be held on Wednesday, March 23, 2011 at 11:00 am EST.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.  A replay of the call will be available starting on March 23, 2011 at 1:00 pm EST, through March 30, 2011 until 11:59 pm EST.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 368488. An archived webcast of the conference call also will be available on the Access Pharma website at www.accesspharma.com.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> North America , ... by MarketsandMarkets, The global market is expected to reach USD 20,190.1 ... a CAGR of 10.2%. --> According to a new ...
(Date:2/10/2016)... SINGAPORE , Feb. 11, 2016  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... its ongoing litigation with AngioScore, Inc. ("ÄngioScore") (now ... the United States ... (the "Federal Circuit") reversed an earlier district court ...
(Date:2/10/2016)... PITTSBURGH , 10 februari ... och detta pressmeddelande får inte distribueras, vare ... och inga anmälningssedlar kommer att accepteras från ... land där Erbjudandet, distribution av detta pressmeddelande ... strida mot tillämpliga lagar eller regler eller ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... , ... The annual list showcases the 20 Most Promising SharePoint Solution Providers ... and commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s ... recognize and promote technology entrepreneurship. , The survey was made at the end ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ergoFET force gauges used in physical therapy, occupational therapy and sports medicine clinics, ... resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led by Providence Health ... common cancer screenings, especially among women. Cancer screenings are often the best way ... The study,“What Does Medicaid Expansion Mean for Cancer Screening and Prevention: Results from ...
Breaking Medicine News(10 mins):